Skip to main content
PMC home page
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2019 Apr 5;10:418. doi: 10.3389/fphar.2019.00418

Erratum: Cannabinoid Receptor 2 Signalling Bias Elicited by 2,4,6-Trisubstituted 1,3,5-Triazines

Frontiers Production Office1,*
PMCID: PMC6460767  PMID: 31024325

Due to a production error, 24 references with more than six authors were listed in the Reference list without “et al.” The references affected are Bouaboula et al. (1993, 1996); Felder et al. (1995); Galiegue et al. (1995); Favata et al. (1998); Portier et al. (1999); Kilts et al. (2002); Karsak et al. (2005); Wright et al. (2005); Ofek et al. (2006); Jiang et al. (2007); Valant et al. (2008); Cencioni et al. (2010); Hurst et al. (2010); Schuehly et al. (2011); van der Stelt et al. (2011); Kleyer et al. (2012); Odan et al. (2012); Shonberg et al. (2013); Brailoiu et al. (2014); Herenbrink et al. (2016); Finlay et al. (2017); Soethoudt et al. (2017) and Yrjölä et al. (2015).

The publisher apologizes for this mistake. The original version of this article has been updated.

References

  1. Bouaboula M., Poinot-Chazel C., Marchand J., Canat X., Bourrie B., Rinaldi-Carmona M., et al. (1996). Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur. J. Biochem. 237, 704–711. 10.1111/j.1432-1033.1996.0704p.x [DOI] [PubMed] [Google Scholar]
  2. Bouaboula M., Rinaldi M., Carayon P., Carillon C., Delpech B., Shire D., et al. (1993). Cannabinoid-receptor expression in human leukocytes. Eur. J. Biochem. 214, 173–180. 10.1111/j.1432-1033.1993.tb17910.x [DOI] [PubMed] [Google Scholar]
  3. Brailoiu G. C., Deliu E., Marcu J., Hoffman N. E., Console-Bram L., Zhao P., et al. (2014). Differential activation of intracellular versus plasmalemmal CB2 cannabinoid receptors. Biochemistry 53, 4990–4999. 10.1021/bi500632a [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cencioni M. T., Chiurchiu V., Catanzaro G., Borsellino G., Bernardi G., Battistini L., et al. (2010). Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS ONE 5:e8688. 10.1371/journal.pone.0008688 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Favata M. F., Horiuchi K. Y., Manos E. J., Daulerio A. J., Stradley D. A., Feeser W. S., et al. (1998). Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273, 18623–18632. 10.1074/jbc.273.29.18623 [DOI] [PubMed] [Google Scholar]
  6. Felder C. C., Joyce K. E., Briley E. M., Mansouri J., Mackie K., Blond O., et al. (1995). Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 48, 443–450. [PubMed] [Google Scholar]
  7. Finlay D. B., Cawston E. E., Grimsey N. L., Hunter M. R., Korde A., Vemuri V. K., et al. (2017). Gas signalling of the CB1 receptor and the influence of receptor number. Br. J. Pharmacol. 174, 2545–2562. 10.1111/bph.13866 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P., et al. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232, 54–61. [DOI] [PubMed] [Google Scholar]
  9. Herenbrink C. K., Sykes D. A., Donthamsetti P., Canals M., Coudrat T., Shonberg J., et al. (2016). The role of kinetic context in apparent biased agonism at GPCRs. Nat. Commun. 7:10842 10.1038/ncomms10842 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hurst D. P., Grossfield A., Lynch D. L., Feller S., Romo T. D., Gawrisch K., et al. (2010). A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor. J. Biol. Chem. 285, 17954–17964. 10.1074/jbc.M109.041590 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Jiang L. I., Collins J., Davis R., Lin K.-M., DeCamp D., Roach T., et al. (2007). Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-Phosphate/G(13) pathway. J. Biol. Chem. 282, 10576–10584. 10.1074/jbc.M609695200 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Karsak M., Cohen-Solal M., Freudenberg J., Ostertag A., Morieux C., Kornak U., et al. (2005). Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum. Mol. Genet. 14, 3389–3396. 10.1093/hmg/ddi370 [DOI] [PubMed] [Google Scholar]
  13. Kilts J. D., Connery H. S., Arrington E. G., Lewis M. M., Lawler C. P., Oxford G. S., et al. (2002). Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. J. Pharmacol. Exp. Ther. 301, 1179–1189. 10.1124/jpet.301.3.1179 [DOI] [PubMed] [Google Scholar]
  14. Kleyer J., Nicolussi S., Taylor P., Simonelli D., Furger E., Anderle P., et al. (2012). Cannabinoid receptor trafficking in peripheral cells is dynamically regulated by a binary biochemical switch. Biochem. Pharmacol. 83, 1393–1412. 10.1016/j.bcp.2012.02.014 [DOI] [PubMed] [Google Scholar]
  15. Odan M., Ishizuka N., Hiramatsu Y., Inagaki M., Hashizume H., Fujii Y., et al. (2012). Discovery of S-777469: an orally available CB2 agonist as an antipruritic agent. Bioorg. Med. Chem. Lett. 22, 2803–2806. 10.1016/j.bmcl.2012.02.072 [DOI] [PubMed] [Google Scholar]
  16. Ofek O., Karsak M., Leclerc N., Fogel M., Frenkel B., Wright K., et al. (2006). Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc. Natl. Acad. Sci. U.S.A. 103, 696–701. 10.1073/pnas.0504187103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Portier M., Rinaldi-Carmona M., Pecceu F., Combes T., Poinot-Chazel C., Calandra B., et al. (1999). SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist. J. Pharmacol. Exp. Ther. 288, 582–589. [PubMed] [Google Scholar]
  18. Schuehly W., Paredes J. M., Kleyer J., Huefner A., Anavi-Goffer S., Raduner S., et al. (2011). Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists. Chem. Biol. 18, 1053–1064. 10.1016/j.chembiol.2011.05.012 [DOI] [PubMed] [Google Scholar]
  19. Shonberg J., Herenbrink C. K., López L., Christopoulos A., Scammells P. J., Capuano B., et al. (2013). A structure–activity analysis of biased agonism at the dopamine D2 receptor. J. Med. Chem. 56, 9199–9221. 10.1021/jm401318w [DOI] [PubMed] [Google Scholar]
  20. Soethoudt M., Grether U., Fingerle J., Grim T. W., Fezza F., de Petrocellis L., et al. (2017). Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity. Nat. Commun. 8:13958. 10.1038/ncomms13958 [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Valant C., Gregory K. J., Hall N. E., Scammells P. J., Lew M. J., Sexton P. M., et al. (2008). A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J. Biol. Chem. 283, 29312–29321. 10.1074/jbc.M803801200 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. van der Stelt M., Cals J., Broeders-Josten S., Cottney J., van der Doelen A. A., Hermkens M., et al. (2011). Discovery and optimization of 1-(4-(Pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives as a novel class of selective cannabinoid CB2 receptor agonists. J. Med. Chem. 54, 7350–7362. 10.1021/jm200916p [DOI] [PubMed] [Google Scholar]
  23. Wright K., Rooney N., Feeney M., Tate J., Robertson D., Welham M., et al. (2005). Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 129, 437–453. 10.1016/j.gastro.2005.05.026 [DOI] [PubMed] [Google Scholar]
  24. Yrjölä S., Sarparanta M., Airaksinen A. J., Hytti M., Kauppinen A., Pasonen-Seppänen S., et al. (2015). Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists. Eur. J. Pharm. Sci. 67, 85–96. 10.1016/j.ejps.2014.11.003 [DOI] [PubMed] [Google Scholar]

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES